Danish drug maker Novo Nordisk plans to open new factories in North Carolina and Denmark to meet growing demands for diabetes medications.
Novo says it will invest a total of $2 billion over the next five years in new production facilities in Clayton, North Carolina and near Copenhagen, Denmark. This will create close to 700 new production and engineering jobs in Clayton at what will be Novo's first API plant in the U.S., as well as about 100 jobs at the new Danish factory producing oral products, including a new drug Novo Nordisk announced was entering further human trials.
According to the company, Nova was promised nearly $19 million in tax breaks, grants and worker training from North Carolina's state government. Production is expected to begin by 2020.
Read the AP News story